236 related articles for article (PubMed ID: 30018513)
1. Presurgical Identification of Uterine Smooth Muscle Malignancies through the Characteristic FDG Uptake Pattern on PET Scans.
Ho KC; Dean Fang YH; Lin G; Ueng SH; Wu TI; Lai CH; Chueh HY; Chao A; Chang TC; Yen TC
Contrast Media Mol Imaging; 2018; 2018():7890241. PubMed ID: 30018513
[TBL] [Abstract][Full Text] [Related]
2. Uterine smooth muscle tumours with hyperintense area on T
Ando T; Kato H; Furui T; Morishige KI; Goshima S; Matsuo M
Br J Radiol; 2018 Apr; 91(1084):20170767. PubMed ID: 29308922
[TBL] [Abstract][Full Text] [Related]
3. Ki-67 expression in patients with uterine leiomyomas, uterine smooth muscle tumors of uncertain malignant potential (STUMP) and uterine leiomyosarcomas (LMS).
Mayerhofer K; Lozanov P; Bodner K; Bodner-Adler B; Kimberger O; Czerwenka K
Acta Obstet Gynecol Scand; 2004 Nov; 83(11):1085-8. PubMed ID: 15488127
[TBL] [Abstract][Full Text] [Related]
4. Bcl-2 receptor expression in patients with uterine smooth muscle tumors: an immunohistochemical analysis comparing leiomyoma, uterine smooth muscle tumor of uncertain malignant potential, and leiomyosarcoma.
Bodner K; Bodner-Adler B; Kimberger O; Czerwenka K; Mayerhofer K
J Soc Gynecol Investig; 2004 Apr; 11(3):187-91. PubMed ID: 15051039
[TBL] [Abstract][Full Text] [Related]
5. Ultrasound features of highly vascularized uterine myomas (uterine smooth muscle tumors) and correlation with histopathology.
Russo C; Camilli S; Martire FG; Di Giovanni A; Lazzeri L; Malzoni M; Zupi E; Exacoustos C
Ultrasound Obstet Gynecol; 2022 Aug; 60(2):269-276. PubMed ID: 35018681
[TBL] [Abstract][Full Text] [Related]
6. Expression of matrix metalloproteinases in patients with uterine smooth muscle tumors: an immunohistochemical analysis of MMP-1 and MMP-2 protein expression in leiomyoma, uterine smooth muscle tumor of uncertain malignant potential, and leiomyosarcoma.
Bodner-Adler B; Bodner K; Kimberger O; Czerwenka K; Leodolter S; Mayerhofer K
J Soc Gynecol Investig; 2004 Apr; 11(3):182-6. PubMed ID: 15051038
[TBL] [Abstract][Full Text] [Related]
7. 18F-FLT PET performs better than 18F-FDG PET in differentiating malignant uterine corpus tumors from benign leiomyoma.
Yamane T; Takaoka A; Kita M; Imai Y; Senda M
Ann Nucl Med; 2012 Jul; 26(6):478-84. PubMed ID: 22477262
[TBL] [Abstract][Full Text] [Related]
8. Prognostic significance of preoperative ¹⁸F-FDG PET/CT in uterine leiomyosarcoma.
Park JY; Lee JW; Lee HJ; Lee JJ; Moon SH; Kang SY; Cheon GJ; Chung HH
J Gynecol Oncol; 2017 May; 28(3):e28. PubMed ID: 28382795
[TBL] [Abstract][Full Text] [Related]
9. Use of 18F-fluorodeoxyglucose positron emission tomography for diagnosis of uterine sarcomas.
Nagamatsu A; Umesaki N; Li L; Tanaka T
Oncol Rep; 2010 Apr; 23(4):1069-76. PubMed ID: 20204293
[TBL] [Abstract][Full Text] [Related]
10. 18F-FES and 18F-FDG PET for differential diagnosis and quantitative evaluation of mesenchymal uterine tumors: correlation with immunohistochemical analysis.
Zhao Z; Yoshida Y; Kurokawa T; Kiyono Y; Mori T; Okazawa H
J Nucl Med; 2013 Apr; 54(4):499-506. PubMed ID: 23471314
[TBL] [Abstract][Full Text] [Related]
11. Preoperative [
Lee JW; Park JY; Lee HJ; Lee JJ; Moon SH; Kang SY; Cheon GJ; Chung HH
Eur J Nucl Med Mol Imaging; 2018 Jul; 45(8):1309-1316. PubMed ID: 29492644
[TBL] [Abstract][Full Text] [Related]
12. Standardized uptake values of uterine leiomyoma with 18F-FDG PET/CT: variation with age, size, degeneration, and contrast enhancement on MRI.
Kitajima K; Murakami K; Yamasaki E; Kaji Y; Sugimura K
Ann Nucl Med; 2008 Jul; 22(6):505-12. PubMed ID: 18670857
[TBL] [Abstract][Full Text] [Related]
13. Uterine Leiomyosarcoma: Can MRI Differentiate Leiomyosarcoma From Benign Leiomyoma Before Treatment?
DeMulder D; Ascher SM
AJR Am J Roentgenol; 2018 Dec; 211(6):1405-1415. PubMed ID: 30354268
[TBL] [Abstract][Full Text] [Related]
14. Expression of p16 protein in patients with uterine smooth muscle tumors: an immunohistochemical analysis.
Bodner-Adler B; Bodner K; Czerwenka K; Kimberger O; Leodolter S; Mayerhofer K
Gynecol Oncol; 2005 Jan; 96(1):62-6. PubMed ID: 15589581
[TBL] [Abstract][Full Text] [Related]
15. Incidence and characteristics of uterine leiomyomas with FDG uptake.
Nishizawa S; Inubushi M; Kido A; Miyagawa M; Inoue T; Shinohara K; Kajihara M
Ann Nucl Med; 2008 Nov; 22(9):803-10. PubMed ID: 19039559
[TBL] [Abstract][Full Text] [Related]
16. 18F-fluorodeoxyglucose uptake in uterine leiomyomas in healthy women.
Tsukada H; Murakami M; Shida M; Kikuchi K; Watanabe M; Yasuda S; Suzuki Y
Clin Imaging; 2009; 33(6):462-7. PubMed ID: 19857807
[TBL] [Abstract][Full Text] [Related]
17. Expression of thrombospondin 1 (TSP 1) in patients with uterine smooth muscle tumors: an immunohistochemical study.
Bodner-Adler B; Nather A; Bodner K; Czerwenka K; Kimberger O; Leodolter S; Mayerhofer K
Gynecol Oncol; 2006 Oct; 103(1):186-9. PubMed ID: 16595146
[TBL] [Abstract][Full Text] [Related]
18. High 18F-FDG uptake for uterine smooth muscle tumor of uncertain malignant potential.
Zhang R; Tian X; Qin L; Lu D; Shen J
Clin Nucl Med; 2015 Apr; 40(4):349-51. PubMed ID: 25674868
[TBL] [Abstract][Full Text] [Related]
19. Estrogen and progesterone receptor expression in patients with uterine smooth muscle tumors.
Bodner K; Bodner-Adler B; Kimberger O; Czerwenka K; Mayerhofer K
Fertil Steril; 2004 Apr; 81(4):1062-6. PubMed ID: 15066464
[TBL] [Abstract][Full Text] [Related]
20. Assessment of fluorodeoxyglucose uptake by leiomyomas in relation to histopathologic subtype and the menstrual state.
Yoshida Y; Tsujikawa T; Kurokawa T; Tsuji T; Imamura Y; Fujibayashi Y; Okazawa H; Kotsuji F
J Comput Assist Tomogr; 2009; 33(6):877-81. PubMed ID: 19940654
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
